Akero Therapeutics Other Current Liabilities

Akero Therapeutics (AKRO) currently reports a other current liabilities of $26M as of September 2025. That compares with $17M in the prior-year period — up 51.3% year over year. Use the charts on this page to explore Akero Therapeutics's other current liabilities history and peer comparisons.

Akero Therapeutics's other current liabilities increased from $17M to $26M — a 51.3% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Akero Therapeutics reported $26M in other current liabilities as of September 2025. That compares with $17M in the prior-year period — up 51.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $26M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Akero Therapeutics, and consider following AKRO for alerts when major investors trade the stock.

Akero Therapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $26M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AKRO with unrelated industries.